Engineered immune cells for relapsed neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 1 to 12 years, weighing at least 22 pounds (10 kg)
- Has neuroblastoma that returned after treatment or did not fully respond to standard therapy
- Tumor tested positive for B7-H3 (a protein on the cancer cells)
- Can have at least one tumor seen on a MIBG scan or bone marrow test
- Child is well enough to get out of bed and play (Lansky score above 60)
- Major organs like heart, lungs, liver, kidneys, and blood counts are working adequately
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
Hear when a new Neuroblastoma, Recurrent, Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.